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Improvements in immunosuppression have reduced acute kidney allograft rejection and clinicians are now
seeking ways to prolong allograft survival to 20 years and beyond. The primary cause of kidney allograft loss is
still chronic rejection, followed by death with a functioning allograft and primary kidney disease recurrence.
Thus, overcoming kidney allograft rejection remains the most important issue. Kidney allograft rejection can be
classified into two types: T cell- and antibody-mediated rejection. Both are diagnosed pathologically based on
the Banff 2013 classification. Other important pathological features in addition to rejection include calcineurin
inhibitor toxicity, polyomavirus nephropathy, and recurrence of the primary kidney disease. Here, we review the
diagnosis and representative features of histopathological findings in transplanted kidneys.
Keywords: Transplant kidney pathology, Antibody-mediated rejection, T cell-mediated rejection, Calcineurin
inhibitor (CNI) nephrotoxicity, Polyoma virus nephropathy, Recurrence of primary kidney diseaseBackground
Kidney transplantation enhances the quality of life and
patient survival in end-stage renal disease (ESRD). The
total number of kidney transplantations has increased
1.6-fold over the past decade in Japan. The Japanese
Society for Clinical Renal Transplantation (JSCRT) re-
ported that the total number of renal transplantations in
2015 was 1661 versus 994 in 2005. JSCRT data obtained
since 2000 showed that the 10-year patient and graft
survival times were 93.8 and 80.2%, respectively (http://
www.asas.or.jp/jst/pdf/factbook/factbook/2015.pdf ).
Reasons for graft loss were primarily chronic rejection
(47%), followed by acute rejection (6.2%), and recurrence of
the original kidney disease (1.8%) (http://www.asas.or.jp/jst/
pdf/factbook/factbook2015.pdf). These data clearly suggest
that the diagnosis and treatment of kidney allograft
rejection remains the most important issue. Rates of
acute rejection in the first year post-transplant have im-
proved consistently since 2008 and remain similar for
deceased- and living-donor recipients. For the period
2012–2013, only 8.5% of patients with deceased-donor
kidneys and 8.1% with living-donor kidneys experienced* Correspondence: izumi26@jikei.ac.jp
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after kidney transplantation [1]. Risk factors for acute
rejection—T cell- and/or antibody-mediated—include
the degree of histocompatibility between the donor and
recipient, the level of presensitization [previous graft,
pregnancy, blood transfusion], immunosuppressive
drug regimens, and the level of patient adherence with
daily therapy [2]. Current immunosuppressive drug
protocols with calcineurin inhibitors (CNIs), steroids,
and mycophenolate mofetil (MMF) have reduced the
frequency of acute T cell-mediated rejection (TCMR)
considerably [3].
Kidney allograft rejection can be classified into two
types: T cell- and antibody-mediated rejection (ABMR).
Both are diagnosed pathologically based on the Banff
2013 classification. The Banff meeting, firstly started in
1991 by Prof. Kim Solez of University of Alberta, is a
consensus meeting regarding allograft pathology that has
been held every 2 years. The latest version of the Banff
classification was prepared in 2013. The Banff classification
consists of the following six categories: (1) normal, (2)
ABMR, (3) borderline changes, (4) TCMR, (5) interstitial
fibrosis and tubular atrophy (IF/TA), and (6) other. It
should be noted that not only rejection but also additional
histopathological findings, such as CNI toxicity and poly-
omavirus nephropathy, may overlap [4]. Here, we introducele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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pathological findings from transplanted kidneys.
Kidney allograft rejection
ABMR
ABMR was first recognized in 1996 in the form of hyper-
acute rejection in patients with pre-transplant donor-
specific antibodies (DSAs) [5]. DSAs, largely reactive to
human leukocyte antigens (HLAs), are now recognized as a
significant cause of ABMR [6]. In the Banff classification,
ABMR is divided into two types: acute/active ABMR (acute
ABMR) and chronic/active ABMR (chronic ABMR).
Acute ABMR occurs in patients who develop a threshold
level of antidonor antibodies after transplantation or who
were presensitized and transplanted after desensitization.
Acute ABMR occurs most commonly 1–3 weeks after
transplantation, particularly in desensitized patients, but
can develop suddenly at any time. The primary risk factor
for acute ABMR is presensitization [blood transfusion,
pregnancy, prior transplant], as judged by a historical posi-
tive cross-match or high levels of panel-reactive antibody
(PRA), flow cytometry cross-match, or LABScreen methods
[6, 7].
In contrast, chronic ABMR typically presents insidi-
ously, several years after transplantation. Chronic ABMR
develops through a number of stages over many months
to years [8]. The mechanism for the development of
chronic ABMR consists of four steps:(1) de novo DSA
production, (2) interaction of de novo DSA with the
microvascular endothelium, resulting in C4d positivity,
(3) specific histopathological changes, such as transplant
glomerulopathy and peritubular capillary basement
membrane multilayering accompanied by microvascular
inflammation, and (4) increased serum creatinine. This
sequence is based on several observations. For example,
in non-presensitized patients, de novo DSA preceded
the onset of proteinuria by an average of 9 months and
the onset of elevated serum creatinine by 12 months [9].
Additionally, Regele et al. showed that, in the first year
post-transplant, patients with C4d+ biopsies had a higher
frequency of transplant glomerulopathy (TG) and rep-
resentative histopathology of chronic ABMR in later
biopsies [10].
In the past decade, it has become clear that late-graft
failure is often due to chronic ABMR [9, 11]. Indeed,
~60% of late-graft failure is due to chronic ABMR [12].
The histological features of acute ABMR are not abso-
lutely specific and are thus insufficient alone for a defini-
tive diagnosis. The Banff 2013 classification included a
scheme for ABMR that required both pathological and
clinical laboratory elements, as follows: (1) characteristic
histological manifestations of both acute and chronic
ABMR, (2) DSA-induced endothelial cell injury, repre-
sented by C4d positivity, microvascular inflammation(MVI), or the expression of activated endothelial gene
transcripts (ENDATs), and (3) DSA positivity (Table 1).
Characteristic histological manifestations of acute ABMR
Histological evidence of acute ABMR has been divided into
four types, based on light microscopy: (1) MVI with neutro-
phils and mononuclear cells in capillaries (i.e., transplant
glomerulitis and peritubular capillaritis) (Fig. 1a, b), (2)
intimal or transmural arteritis (Fig. 1c), (3) acute throm-
botic microangiopathy (TMA) (Fig. 1d), and (4) acute
tubular injury in the absence of any other cause. Transplant
glomerulitis is characterized histologically by glomerular
MVI and the enlargement of endothelial cells. Glomerular
capillaries have neutrophils in 10–55% and mononuclear
glomerulitis in 19–90% [13, 14] of cases (Fig. 1a). In the
Banff 2013 classification, determination of the numerical
transplant glomerulitis (g) score was still based on the per-
centage of glomeruli involved [15]: 1–25, 26–50, and >50%
for g1, g2, and g3, respectively (Table 2). Indeed, the scoring
of glomerulitis based on these fractions of involved glom-
eruli using the definition above was superior to scoring
based on numbers of leukocytes per glomerulus, even when
CD68 staining was added. In addition to these conventional
criteria, endothelial swelling and capillary occlusion were
adopted as a definition of transplant glomerulitis at the
Banff 2013 meeting [16].
Peritubular capillaritis shows findings of dilated peri-
tubular capillaries (PTCs) containing three to four more
inflammatory cells per cross section in more than 10%
of PTCs in non-atrophic cortex. Determination of the
peritubular capillaritis (ptc) score is based on the number
of inflammatory cells involved: 3–4, 5–10, and >10 for
ptc1, ptc2, and ptc3, respectively (Fig. 1b). The scores refer
to the highest number of cells in a single PTC (Table 2).
Diffuse capillaritis in early protocol biopsies showed a sig-
nificant negative prognostic impact in terms of glomerular
filtration rate 2 years later. Subsequent work on the speci-
ficity and sensitivity of capillaritis, by Sis et al. in 329 indi-
cation biopsies [17], revealed peritubular capillaritis in not
only 75% of acute and chronic ABMR biopsies but also in
acute TCMR and acute tubular necrosis. The authors con-
cluded that the g-score + the ptc-score sum, the MVI, was
the best predictor of DSA, followed by time post-
transplant in late-graft biopsies. We suggested that lymph-
atic vessels should be excluded by podoplanin staining to
score ptc in confusing cases [18].
Intimal or transmural arteritis, defined by the infiltration
of mononuclear cells under enlarged and “activated” arterial
endothelial cells (primarily arcuate caliber vessels or inter-
lobular arteries, and less often arterioles), has been scored
according to the degree of luminal narrowing: <25%, ≥25%,
and transmural necrosis for v1, v2, and v3, respectively
(Table 2) (Fig. 1c). Intimal or transmural arteritis has long
been categorized as a typical lesion of acute TCMR;
Table 1 The Banff 2013 classification
1. Normal
2. Antibody-mediated
Acute/active ABMR; all three features must be present for diagnosis
1. Histologic evidence of acute tissue injury, including one or more
of the following:
Microvascular inflammation (g > 0 and/or ptc > 0)
Intimal or transmural arteritis (v > 0)
Acute thrombotic microangiopathy, in the absence of any other
cause
2. Evidence of current/recent antibody interaction with vascular
endothelium, including at least one of the following:
Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF
on frozen sections, or C4d > 0 by IHC on paraffin sections)
At least moderate microvascular inflammation ([g +ptc] > 2)
Increased expression of gene transcripts in the biopsy tissue
indicative of endothelial injury if thoroughly validated
3. Serologic evidence of donor-specific antibodies (DSAs) (HLAor
other antigens)
Chronic, active ABMR; all three features must be present for diagnosis
1. Morphologic evidence of chronic tissue injury, including one or
more of the following:
Transplant glomerulopathy (TG) (eg > 0), if no evidence of
chronic thrombotic microangiopathy Severe peritubular capillary
basement membrane multilayering (requires EM)
Arterial intimal fibrosis of new onset, excluding other causes
2. Evidence of current/recent antibody interaction with vascular
endothelium, including at least one of the following:
Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF
on frozen sections, or C4d > 0 by IHC on paraffin sections)
At least moderate microvascular inflammation ([g +ptc] > 2)
Increased expression of gene transcripts in the biopsy tissue
indicative of endothelial injury, if thoroughly valiated
3. Serologic evidence of DSAs (HLA or other antigens)
C4d staining without evidence of rejection; all three features must be
present for diagnosis
1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF
on frozen sections, or C4d > 0 by IHC on paraffin sections)
2. g = 0, ptc = 0, eg = 0 (by light microscopy and by EM if
available), v = 0; no TMA, no peritubular capillary basement
membrane multilayering, no acute tubular injury (in the absence
of another apparent cause for this)
3. No acute cell-mediated rejection (Banff 97 type 1A or greater) or
borderline changes
3. Borderline changes: ‘Suspicious’ for acute T-cell mediated rejection
(may coincide with categories 2 and 5, and 6)
This category is used when no intimal arteritis is present, but there
are foci of tubulitis (t1, t2, or t3) with minor interstitial infiltration (i0,
or i1) or interstitial infiltration (i2, i3) with mild (t1) tubulitis
4. T cell mediated rejection (TCMR, may coincide with categories 2 and
5 and 6)
Table 1 The Banff 2013 classification (Continued)
Acute T-cell mediated rejection (Type/Grade:)
I A. Cases with significant interstitial infiltration (>25% of
parenchyma affected, i2 or i3) and foci of moderate tubulitis (t2)
I B. Cases with significant interstitial infiltration (>25% of
parenchyma affected, i2 or i3) and foci of severe tubulitis (t3)
II A. Cases with mild to moderate intimal arteritis (v1)
II B. Cases with sever intimal arteritis comprising >25% of the
luminal area (v2)
III. Cases with ‘transmural’ arteritis and/or arterial fibrinoid change
and necrosis of medial smooth muscle cells with accompanying
lymphocytic inflammation (v3)
Chronic active T-cell mediated rejection
‘chronic allograft aiteriopathy’ (arterial intimal fibrosis with
mononuclear cell infiltration in fibrosis, formation of neo-intima)
5. Interstitial fibrosis and tubular atrophy, no evidence of any specific
etiology
(may include nonspecific vascular and glomerular sclerosis, but
severity graded by tubulointerstitial features)
I. Mild interstitial fibrosis and tubular atrophy (>25% of cortical area)
II. Moderate interstitial fibrosis and tubular atrophy (26-50% of
cortical area)
III. Sever interstitial fibrosis and tubular atrophy/loss (>50% of
cortical area)
6. Other: Changes not considered to be due to rejection-acute and/or
chronic
(For diagnoses see table 14 in (Banff 97 KI -1999:)[15]); may include
isolated g, eg, or cv lesions and coincide with categories 2, 3,4, and 5)
Modified Table of ref. [16]
cg Banff chronic glomerulopathy score, EM electron microscopy, ENDAT
endothelial activation and injury transcript, g Banff glomerulitis score,
GBM glomerular basement membrane, IF immunofluorescence, IHC
immunohistochemistry, ptc peritubular capillary, TCMR T cell-mediated
rejection, v Banff arteritis score
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of intimal or transmural arteritis was more often observed
in cases with acute ABMR (21%) than TCMR (9%), and the
grade of intimal arteritis in acute ABMR was 52% in v1,
followed by 30% in v2, and 19% in v3. [19]. These patho-
logical features correlated historically with increased graft
loss in acute rejection with fibrinoid necrosis of the arteries
(type III), with ~25% graft survival at 1 year [20, 21].
Recently, isolated endarteritis in kidney transplants has
become an increasingly recognized and reported entity
[22], but identification of the mechanisms underlying the
arterial lesions remains problematic. Salazar ID et al. [23]
suggested that after 1-year post-transplant, isolated v
lesions usually indicate rejection. Many such cases are
DSA-positive and have acute ABMR, but some may reflect
TCMR, particularly at less than 5 years post-transplant.
Although it has not yet been established about the need
and the contents of the antirejection treatment to isolated v
lesion, a recent report showed the efficacy of antirejection
Fig. 1 Pathological findings of acute antibody-mediated rejection. a Transplant glomerulitis (Banff classification; g) in a patient with ABMR. Most
of the endothelial cells were swelling and inflammatory cells including mononuclear cells and neutrophils were present with focal occlusion in glomerular
capillaries. [PAM, ×400]. b Peritubular capillaritis (Banff classification; ptc) in a patient with antibody-mediated rejection (ABMR). Peritubular capillaries (PTCs)
were markedly dilated, and inflammatory cells including mononuclear cells and neutrophils were present in PTCs [HE, ×400]. c Transplant endoarteritis
(Banff classification; v) in a patient with ABMR. Endothelial cells of interlobular artery were swelling and marked inflammatory cells infiltration narrowed the
lumen [PAS, ×400]. d Thrombotic microangiopathy in a patient with ABMR. The dilated capillary lumen was occluded by a fibrin thrombus in glomerulus
focally, and the fragment red blood cells were present in mesangial lesion. Endothelial cells were swelling and capillary walls were dilated
with subendothelial widening [Masson Trichrome, ×400]




0 1 2 3
Interstitial inflammation (% of nonfibrotic cortex) i <10% 10–25% 26–50% >50%
Total inflammation (% all cortex) ti <10% 10–25% 26–50% >50%
Tubulitis (maximum mononuclear cells/tubule) t 0 1–4 5–10 >10
Arterial inflammation (% lumen endarteritis) V None <25% >25% Transmural or necrosis
Glomerulitis (% glomeruli involved) g None <25% 26–50% >50%
Capillaritis (cells per cortical PTC, requires >10% of PTC to be affected for scoring) ptc <10% <5/PTC 5–10/PTC >10/PTC
C4d deposition in PTC (% positive) C4d 0% l–9% 10–50% >50%
Interstitial fibrosis (% of cortex) ci <5% 6–25% 26–50% >50%
Tubular atrophy (% cortex) ct 0% <25% 26–50% >50%
Arterial intimal thickening (% narrowing lumen of most severely affected glomerulus) cv 0% <25% 26–50% >50%
Transplant glomerulopathy (% of capillaries with duplication in most severely affected
glomerulus)
cg 0% <25% 26–50% >50%
Arteriolar hyalinosis (number with focal or circumferential hyaline) ah None 1 focal >1 focal 1 circumferential >50%
Mesangial matrix increase (% affected glomeruli) mm 0% <25% 26–50% >50%
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followed by antithymocyte globulin [23].
Acute TMA, characterized by endothelial swelling and
subendothelial widening, fibrin thrombi in capillary lumens,
mesangiolysis, and fragmented red blood cells in the suben-
dothelium and mesangium, occurs in several diseases
(Fig. 1d). Acute ABMR has emerged as a significant cause
of TMA, based on the occurrence of TMA being higher in
cases that were PTC C4d+ (13.6%) versus PTC C4d− (3.6%).
Moreover, plasma exchange was effective in TMA cases
with PTC C4d positivity [24]. An acute tubular necrosis-
like histology with minimal inflammation can also occur in
cases with acute ABMR.
Characteristic histological manifestations of chronic ABMR
Histological evidence of chronic ABMR includes three
types: (1) TG type, (2) severe PTC basement membrane
multilayering type, and (3) arterial intimal fibrosis of
new onset type. The most characteristic feature of
chronic ABMR is TG, defined as the widespread duplica-
tion or multilayering of glomerular basement membrane
(GBM) in the absence of specific de novo or recurrent
glomerular disease or evidence of TMA (Fig. 2a). TG
develops in stages, best seen by electron microscopyFig. 2 Pathological findings of chronic antibody-mediated rejection. a Tran
walls were duplicated diffusely and narrowed capillary lumens were marke
[PAS, ×400]. b Transplant arteriopathy (Banff classification;cv) The intima in
elastic fibers, in which a few mononuclear inflammatory cells were include
of the basement membrane in PTCs (arrow). Light microscopic findings sho
as same as tubular basement membranes [PAS, ×400]. d Electron microsco
outside (arrow). Mononuclear cells were present in PTCs and endothelial ce
immunostaining in dilated PTCs was linearly positive with inflammatory ce(EM), and these stages have been related to chronic
ABMR recently [25].
In addition to these chronic features, signs of activity
are often present, with prominent mononuclear cells in
capillary loops with endothelial swelling (transplant glo-
merulitis) [26]. The cells are primarily monocytes, with
few T cells. There is no known specific tubular or intersti-
tial lesion in chronic ABMR. The median time of diagno-
sis for TG by indication biopsies is 5–8 years [27, 28]. The
risk of TG is increased by the presence of higher levels of
class II DSA [29], particularly those reactive to HLA-DQ
which was refractory to conventional therapy [30, 31]. A
history of acute ABMR and presensitization also increases
the risk [29].
TG has a poor prognosis, particularly when accom-
panied by PTC C4d deposition [29, 32]. Lesage et al.
showed recently that TG was associated with a poor
prognosis, independent of the level of graft dysfunction
and other chronic histological changes [33]. Notably,
the early diagnosis of, and therapy for, TG within
3 months may be important for graft survival [25].
Based on these observations, the Banff 2013 meeting
focused on the early diagnosis of TG. The Banff cg0
was defined as no double contours by light microscopysplant glomerulopathy (Banff classification; cg). Glomerular capillary
dly present with endothelial cell swelling and few inflammatory cells
interlobular arteries showed a neointima formation without prominent
d [Masson Trichrome, ×400]. c Transplant capillaropathy, multilayering
wed PTCs in chronic ABMR. Basement membranes of PTCs were thick
py findings showed multilayering of the PTCs basement membrane
ll was swelling. e Positive C4d immunostaining in PTCs of ABMR. C4d
lls presentation in the capillary lumens
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defined: cg1a indicates double contours associated with
subendothelial widening detected only by EM, whereas
cg1b corresponds to one or more glomerular capillaries
with double contours in non-sclerotic glomeruli, observed
by light microscopy [16]. The duplicated GBM, best seen
with periodic acid–Schiff (PAS) or silver staining in light
microscopy, is involved segmentally or globally and may
show mesangial cell interposition. The TG (cg) score is
still based on the most severely affected glomeruli: 1–25,
26–50, and >50% for cg1, cg2, and cg3, respectively
(Table 2).
Multilayering of the basement membrane in PTCs has
been associated with chronic ABMR [10]. Each ring of
basement membrane surrounding a PTC probably repre-
sents the residue of one previous episode of endothelial
injury, from oldest (outer) to most recent (inner) (Fig. 2d).
Ivanyi found that biopsies with three or more PTCs with
seven or more circumferential layers were found only in
patients with other features of chronic rejection [34]. A
subsequent comprehensive study by Liapis et al. compared
native and transplanted kidneys [35]. In this study, higher
threshold levels were set to define severe PTC lamination
(15 PTCs examined, with the three most-affected used for
scoring: severe PTC lamination defined as ≥7 layers in one
capillary and ≥5 layers in the remaining two capillaries).
Based on these observations, severe peritubular basement
membrane multilayering was defined by seven or more
layers in one cortical PTC and five or more in two add-
itional PTCs using EM. Aita et al. demonstrated that
thickening and lamination of the basement membrane
may be seen by light microscopy in favorable PAS- or
silver-stained sections. When the thickness is similar to or
thicker than non-atrophic tubular basement membrane
(TBM), it correlates well with multilayering on EM [36].
Although these light microscopic observations of peritub-
ular basement membrane multilayering might be useful, it
is not incorporated in the current Banff criteria.
The molecular mechanisms involving the endothelium
of the GC and PTC in patients with chronic ABMR are
not fully understood. We previously reported that PV-1
and caveolin-1 expression were a distinct feature of
chronic rejection-induced transplant glomerulopathy
and capillaropathy, respectively [37–39]. More recent
data showed that three markers of endothelial-to-
mesenchymal transition (EndMT), fascin1, vimentin, and
heat shock protein 47 provide a sensitive and reliable
diagnostic tool for detecting endothelial activation
during ABMR [40].
Arterial intimal fibrosis is a typical feature of rejection in
late grafts. These lesions are thought to be caused by anti-
bodies, T cells, or both. Intimal changes are most promin-
ent in the larger arteries, but extend from the main renal
artery to the interlobular arteries. The intima showspronounced fibrous thickening without prominent elastic
fiber accumulation, in contrast to the multilayering of elas-
tic typical of hypertensive and involutive arteriosclerosis
(Fig. 2b) Arterial intimal thickening (cv) scores are still
based on the most severely affected artery: 1–25, 26–50,
and > 50% for cv1, cv2, and cv3, respectively. The elastic
interna generally remains intact. The media generally shows
no obvious abnormality, aside from the focal loss of smooth
muscle.
Arterial lesions are common in allografts caused by
chronic rejection (including ABMR and TCMR), hyper-
tension, and donor disease. Transplant arteriopathy is
associated with DSA in kidney transplants. DSA may
also promote arteriosclerosis, as judged by progression
of severity in allografts from patients with DSA. Loupy
et al. recently suggested that circulating antibodies are
major determinants of severe arteriosclerosis and major
adverse cardiovascular events, independent of traditional
cardiovascular risk factors [41].
C4d positivity, MVI, and ENDAT
To determine DSA-induced endothelial cell injury, the
clinician must confirm one of the following: (1) C4d
positivity in PTC, (2) MVI, or (3) expression of activated
ENDATs. C4d positivity in PTCs has been a cardinal fea-
ture for the diagnosis of both acute and chronic ABMR
since its adoption into the Banff 2005 classification [42].
However, previous report showed the evidence of ABMR
without complement activation demonstrated by transcrip-
tome analysis using ENDATs [43], and now C4d staining
has been considered as one of the criteria to suggest
evidence of endothelial activation triggered by DSA inter-
action. Of note, positive C4d deposition in PTCs without
graft dysfunction in ABO-incompatible kidney transplant-
ation may present accommodation since they do not appear
to be injurious to the renal allografts [44, 45].
In the 2013 Banff classification [16], the threshold for
C4d positivity was modified. In a four-tiered grading
system that ranged from 0 to 3+ (1–9, 10–50, and > 50%
for c4d1, c4d2, and c4d3, respectively; Table 2), C4d
positivity was defined originally as 3+ in both frozen
(immunofluorescence, IF) and paraffin (immunohisto-
chemistry, IHC) sections [46]. The criteria for C4d posi-
tivity were revised to 2+ or 3+ in frozen sections (IF)
and > 0 in paraffin wax sections (IHC) [16] (Fig. 2e)
However, 1+ in frozen sections was not approved unani-
mously as a criterion for C4d positivity. The pattern
tends to be linear and circumferential, similar to that in
acute ABMR; however, fewer positive capillaries are found
and the “widespread” pattern is not common. In chronic
ABMR, PTC C4d deposition was found in ~50% of
the grafts with transplant arteriopathy or glomerulop-
athy [27, 47]. Cases with little or no C4d (C4d0-1)
but demonstrating other features of chronic ABMR
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negative chronic ABMR [48] according to the Banff
2013 classification [16].
The MVI score was defined as the total of the Banff g
+ ptc scores. Recent data showed that the threshold for
moderate MVI (g + ptc ≥ 2) was associated with the
development of overt TG in the presence of DSA, even
in C4d− cases [17, 49]. Gupta et al. showed that MVI
scores of 2 or more were significantly associated with a
histological diagnosis of acute and chronic ABMR using
microarrays [50], confirming the validity of the MVI
score.
The Alberta Transplant Applied Genomics Center
(ATAGC) team at the University of Alberta developed a
“molecular microscope” approach to kidney transplant
biopsies and has provided a system for distinguishing
TCMR from ABMR by the expression of activated
ENDATs. They proposed new rules to integrate molecu-
lar tests and histology into a precise diagnostic system
that can reduce errors, ambiguity, and inter-pathologist
disagreement [51, 52]. Reeve et al. showed that histo-
logical assessments can be improved by placing more
emphasis on i and t lesions and incorporating new algo-
rithms for diagnosis [53]. Halloran et al. recently showed
that ABMR presented distinct subphenotypes—early “pg
(peritubular capillaries and/or glomerulitis lesion)-dom-
inant,” late “cg (GBM double contour)-dominant,” and
combined “pgcg phenotype”—differing in time, molecu-
lar features, accompanying TCMR, HLA antibodies, and
the probability of non-adherence, using a microarray as-
sessment [54]. This combined approach will help in de-
veloping new diagnostic tools and will lead to new
disease classifications. But it has not yet been prevailing
in clinical setting in the present time.
DSA positivity
DSAs may be directed against HLAs or other endo-
thelial cell antigens, and their presence is required
for the diagnosis of acute and chronic, active ABMR
[55]. DSAs bind to HLAs on endothelium and
complement activation is accelerated through the C1
complex. The complement cascade proceeds through
C4, C2, C3, and C5, finally leading to the membrane-
attack complex (MAC) resulting in endothelial cell
lysis.
There is growing evidence supporting risk stratification
according to anti-HLA DSA phenotypes, as follows: (1)
preformed/de novo, (2) mean fluorescence intensity (MFI),
(3) C1q/C3d binding, and (4) immunoglobulin G (IgG)
subclass. Preformed and de novo DSAs are independent
risk factors for acute and chronic ABMR and graft loss
[56–58]. Wiebe et al. [9] followed 365 non-presensitized
patients prospectively with protocol biopsies and serum
samples for DSAs. Overall, 15% developed de novo DSAs,at a mean time of 4.6 years post-transplant. Most patients
developed DSAs to HLA class II (94%); only 6% had anti-
bodies to donor HLA class I alone.
Most of the graft loss in the DSA-positive patients was
due to chronic ABMR (84%). Wiebe also showed in a
subsequent study [58] that, in recipients with de novo
DSAs, the rate of estimated glomerular filtration rate
(eGFR) decline increased significantly prior to de novo
DSA onset and accelerated post-de novo DSAs, suggest-
ing that de novo DSAs were both a marker and con-
tributor to ongoing alloimmunity. Another report
supported the evidence that the risk of acute ABMR and
poor outcome were correlated with the level of MFI of
the DSAs in Luminex assays [59]. Importantly, not all
DSAs fix complement or cause ABMR and, conversely,
not all episodes of acute graft injury with capillary
inflammation and C4d deposition are associated with
DSAs detectable with standard assays. For example,
Loupy et al. demonstrated that C1q-binding DSAs
showed worse graft survival than non-C1q-binding DSA
(HR = 9.23, 95% CI: 5.99–14.23, p < 0.001). Moreover,
the existence of C1q-binding DSA correlated with MVI,
PTC C4d deposition, TG, and IF/TA [60]. Sicard et al.
demonstrated that C3d-binding DSAs showed worse
graft survival than non-C3d-binding DSA [log-rank test,
p = 0.0003]. Additionally, the existence of C3d-binding
DSAs showed better sensitivity (84.7%) and specificity
(73.3%) than C1q-binding DSAs or PTC C4d positivity
[61]. Lefaucheur et al. suggested the clinical relevance of
IgG DSA subclasses and their association with the
phenotype of antibody-mediated injury [62].
Recent studies have focused on DSA other than anti-
HLA antibodies: i.e., non-HLA antibodies. Non-HLA anti-
bodies existed in 2.3% of ABMR cases occurring within
7 days after kidney transplantation [63, 64]. Representative
non-HLA antibodies included MICA, MICB, and angioten-
sin type 1 receptor [AT1R] antibodies [65–68]. Among
these, AT1R antibodies were the most investigated. Banasik
et al. reported that 27 of 117 (23%) patients were positive
for anti-AT1R antibodies prior to surgery and 4 (3.4%)
developed acute rejection [67]. Importantly, Dragun et al.
found that 11 of 16 patients with acute rejection resulting
from anti-AT1R antibodies were C4d− [65]. Beyond this ob-
servation, Reinsmoen et al. evaluated 63 patients with acute
rejection; six cases resulted from anti-AT1R antibodies and
four of them were PTC C4d- [69]. Additionally, Scornik
et al. found no correlation between antibodies to HLA-DP,
MICA, or AT1R and C4d+ rejection [69]. Recently, antivas-
cular endothelial cell antibodies (AECAs: XM-ONE) [70],
and reagents for identification of non-HLAs, non-MICA
antibodies, have become available. Moreover, Jackson et al.
discovered four new non-HLA antibodies: endoglin, Fms-
like tyrosine kinase-3 ligand, EGF-like repeats and discoidin
I-like domains 3, and intercellular adhesion molecule 4. All
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and they were associated with post-transplant DSA, ABMR,
and early TG [71].Treatment of ABMR
The treatment of acute ABMR is still evolving; however,
randomized controlled trials of therapies are rare [72].
The most common strategies are based on the quick
reduction of antibody titers with plasmapheresis (PE),
intravenous immunoglobulin (IVIG), and thymoglobulin
to treat any concurrent TCMR. The best evidence sup-
porting the use of PE and IVIG shows various immuno-
modulatory effects, especially on B cells, antibodies, and
complement. Rituximab, an anti-CD20 monoclonal anti-
body, reacts with CD20 on pre- and mature B cells and
leads to transient B-cell depletion, with B-cell recovery
after 6–9 months. Bortezomib, a proteasome inhibitor
used in the treatment of multiple myeloma for plasma
cell depletion, has been tried in a small cohort with
acute ABMR, with some evidence of success [73, 74].
Eculizumab, an antibody to C5 that blocks the terminal
complement pathway, has shown some efficacy in non-
randomized pilot trials and isolated cases. The efficacy of
eculizumab in the prevention of ABMR was also assessed
in renal transplant recipients with a positive cross-match
[75]. In this study, the authors concluded that despite
decreasing acute clinical ABMR rates, eculizumab-treated
(EC)-positive cross-match kidney transplants did not
prevent chronic ABMR in recipients with persistently high
B flow cytometric cross-matches [76].
Treatment of chronic ABMR remains to be estab-
lished. Strategies have included IVIG and rituximab [77]
and bortezomib [78]. Whether complement inhibition
will be useful remains to be determined. Regular moni-
toring of DSAs and appropriate surveillance biopsies are
recommended [6, 79]. The best intervention is preven-
tion, which remains elusive.TCMR
TCMR was long believed to be the central process in allo-
graft rejection. Consequently, therapies to prevent and treat
allograft rejection were directed primarily against T cells
before ABMR was recognized. In the Banff 2013 classifica-
tion, T cell-mediated rejection (TCMR) included categories
3 (borderline changes) and 4 (acute/chronic TCMR)
(Table 1). TCMR can be divided into two types: acute
TCMR and chronic TCMR. Acute TMCR (Banff category
4, types I–III) is the form of rejection that develops most
commonly in the first several months after transplantation.
TCMR can occur as early as 6 days, and as late as decades,
post-transplantation [1]. The clinical manifestations of
severe acute TCMR include an abrupt increase in serum
creatinine, a decline in urine output, fever, graft tenderness,and swelling, but these symptoms are often absent in
patients under modern immunosuppression.
Characteristic histological manifestations of acute TCMR
Acute TCMR is characterized by tubulitis with inter-
stitial inflammatory cells infiltration and arteritis in
more severe form. In the former, the infiltration of
activated T lymphocytes and macrophages occurs into
a mildly edematous interstitial lesion and into the
tubules, so-called tubulointerstitial cellular rejection
(Banff category 4, type I) (Fig. 3a, b). In the latter, an-
other major finding is the infiltration of mononuclear
cells in the enlarged and activated arterial endothelial
cells, so-called transplant endarteritis (Banff category
4, type II or III). The approximate frequencies of the
different patterns of acute TCMR are 45–70% tubu-
lointerstitial, 30–55% arteritis, and 2–4% glomerular
(not used specifically for the categorization of rejection in
the Banff 2013 classification). Notably, ~20–40% of acute
TCMR cases show C4d positivity along with PTC; that is,
evidence of concurrent antibody-mediated injury [80].
Mixed ABMR and acute TCMR episodes are more severe
and constitute an independent risk factor for graft failure
[19, 81].
Regarding the detailed morphological features of tubu-
lointerstitial cellular rejection, T cells and macrophages
invade tubules and insinuate between tubular epithelial
cells inside the basement membrane, a process termed
“tubulitis” (Fig. 3a, b). Tubulitis is usually recognized by
increased numbers of small, dark nuclei, often arranged
along the inner aspect of the TBM and occasionally sur-
rounded by small clear spaces/halos. In the Banff 2013
classification, determination of the numerical tubulitis
(t) score is based on the maximum number of mono-
nuclear cells in the most affected tubuli: 1–4, 5–10, and
>10 for t1, t2, and t3, respectively (Table 2). Tubulitis
affects mostly distal tubular segments in the cortex;
proximal tubules are often spared and collecting ducts
in the medulla are hardly involved [82]. Tubulitis in dis-
tal segment should be excluded infection which are
commonly extended from proximal site. Contrary to
this, tubulitis in proximal segments means extended
inflammation from distal by rejection. Tubulitis in
atrophic tubules (<50% of the original diameter and
markedly thickened TBMs) is currently considered to be
a non-diagnostic sign of parenchymal scarring; presently,
this feature is not used to establish a diagnosis of acute
TCMR. However, this view may change in the future be-
cause there is increasing evidence that all tubulitis (in
atrophic and non-atrophic tubules) and all interstitial in-
flammation (in scarred and non-scarred regions) is a
sign of TCMR [83].
Mononuclear cell interstitial inflammation was defined
by a pleomorphic interstitial infiltrate of mononuclear cells
Fig. 3 Pathological findings of T cell-mediated rejection, plasma cell-rich rejection, and acute and chronic CNI nephrotoxicity. a Focal aggressive
tubulointerstitial rejection with moderate tubulitis. (Banff classification; i and t) Inflammatory cells were present in the edematous interstitial lesions
and inside of tubular basement membrane staying between tubular epithelial cells (arrow). b Diffuse aggressive tubulointerstitial rejection with
severe tubulitis. (Banff classification; i and t) Massive inflammatory cells were occupied in the interstitium. Partial dissolution and rupture of the
tubular basement membrane were evident (arrow) [Masson Trichrome, ×400]. c Plasma cell-rich acute rejection (PCAR). Tubulointerstitial inflammatory cells
infiltration, which are predominantly plasma cells (arrow) [PAS, ×400]. d Acute CNI nephrotoxicity. The straight portion of proximal tubular epithelial cells
showed isometric vacuolization. e Chronic CNI nephrotoxicity. Arteriole were surrounded by the amorphous materials substitute for the medial smooth
muscle cells
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polymorphonuclear leukocytes in areas of severe tubular
injury. In the Banff 2013 classification, determination of the
numerical interstitial inflammation (i) score is based on the
parenchymal area affected by inflammatory cells: <10–25,
25–50, and >50% for i1, i2, and i3, respectively (Table 2).
Using these t and i scores, tubulointerstitial cellular rejec-
tion includes type IA (i2, 3 with t2) and type IB (i2, 3 with
t3 or at least two areas of TBM destruction and moderate
tubulitis elsewhere).
In acute TCMR, MHC class II/HLA-DR antigens and
intercellular adhesion molecules are expressed, stimulated
by the release of interferon-γ in inflamed regions [84, 85].
The detection of MHC class II in the cytoplasm of tubular
epithelial cells by IF in frozen tissue samples may be used
as an adjunct marker to establish a diagnosis of acute
TCMR.
Regarding the detailed morphological features of trans-
plant endarteritis, infiltration of mononuclear cells under
enlarged and activated arterial endothelial cells, mainly
arcuate-caliber vessels or interlobular arteries, and less
often arterioles, is often observed [endarteritis figure
IIA(v1), IIB(v2), II(v3)] (Table 2). The importance of thislesion has been emphasized for many years and is
accepted widely as a feature of acute TCMR, particu-
larly if transplant endarteritis is accompanied by tubu-
lointerstitial cellular rejection. However, a considerable
proportion of acute TCMR with transplant endarteritis
also shows concurrent acute ABMR [19]. Endarteritis
has been reported in 18–56% of renal biopsies with
acute TCMR [20, 21, 86]. The prevalence of endarter-
itis in biopsies is affected by the sample size, timing of
the biopsy, HLA matching, and the level of immuno-
suppression. Endarteritis tends to affect larger arteries
preferentially [87]. If biopsy samples are small and do
not contain arcuate arteries or interlobular arteries,
such transplant endarteritis may remain undetected. In
cases of endarteritis, endothelial cells are usually acti-
vated, with basophilic cytoplasms, and show lifting
from the supporting elastic intern by infiltrating
inflammatory cells. One inflammatory cell under the
arterial endothelium is considered to be sufficient for
the diagnosis of transplant endarteritis. Mononuclear
inflammatory cells that are solely adherent to the lu-
mina surface of endothelial cells are insufficient for
making a diagnosis of transplant endarteritis.
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because hypertension-induced arterial intimal fibroelas-
tosis gives an intense staining reaction that is lacking in
cases of chronic vascular rejection. In transplant end-
arteritis, inflammation is typically limited to the intima/
subendothelial zone, sparing the medial smooth muscle
layer. Transmural inflammation, involving all layers of
the arterial walls, including segmental fibrinoid necrosis,
can occur in severe cases of acute TCMR (Banff category
4, type III rejection). However, this feature is more often
seen in biopsies with concurrent acute AMR and C4d
positivity [88]. Infiltration of mononuclear cells into the
wall of the veins or lymphatics is found in ~10% of biop-
sies with acute TCMR. This is a sign of inflammatory
cell trafficking in areas of inflammation with no direct
diagnostic significance [89].
The so-called isolated v lesion is characterized by end-
arteritis with minimal interstitial inflammation (i ≤ 1)
and tubulitis (t ≤ 1) [22]. The Banff working group re-
ported that the risk for renal allograft failure was 3.51-
fold higher in patients with isolated v lesions versus a
patient having no diagnostic rejection, concluding that
isolated v lesions should be diagnosed and treated as
acute rejection to prevent long-term kidney transplant
failure [90].
Characteristic histological manifestations of chronic TCMR
In the Banff 2013 classification, chronic TCMR was de-
fined by sclerosing transplant arteriopathy. This lesion is
characterized by intimal widening due to the de novo ac-
cumulation of collagens I and III, lack of elastosis, and
varying degrees of intimal inflammation with mono-
nuclear inflammatory cells. In sclerosing transplant arter-
iopathy, the intima usually contains varying numbers of
myofibroblasts, occasional foam cells, and, in active dis-
ease stages, scattered, often clustered mononuclear in-
flammatory cells that may be most prominent along the
inner elastic lamina. Endothelial cells are often enlarged
with reactive nuclei sometimes overlying an ill-defined
ring of smooth muscle cells: that is, so-called neomedia
formation.
Treatment of TCMR
The first-line treatment for acute cellular rejection (i.e.,
rejection in the absence of C4d staining and/or circulat-
ing DSA) is bolus steroids for up to 3 days. This thera-
peutic approach works well in patients with T cell-
mediated tubulointerstitial rejection (i.e., Banff category
4, type I). In patients who do not respond, primarily
those with transplant endarteritis and glomerulitis, the
standard rescue therapy is thymoglobulin. Certain
pathological features of acute cellular rejection have
prognostic significance. The most important predictors
of outcome are arterial lesions. Endarteritis, whichdefines type II rejection, has an adverse effect on prog-
nosis compared with tubulointerstitial rejection with no
arterial involvement [21]. The intensity of the interstitial
infiltrate, or tubulitis, for that matter, has no correlation
with the severity of the rejection episode [86, 91]. Many,
but not all, “borderline” cases are, indeed, rejection. Un-
treated borderline cases can progress to frank rejection
during follow-up [92]. If there is any evidence that favors
rejection, a diagnosis of rejection should be made and
therapy initiated.
Subclinical rejection
Rejection episodes detected in allografts with stable
function are referred to as “subclinical”. Subclinical
rejection is defined as the presence of histological evi-
dence of acute rejection on a protocol or surveillance
biopsy with no elevation in the serum creatinine level.
Most previous reports of subclinical rejection involved
cellular rejection [93–95]. However, there are reports
of allografts with histological manifestations of ABMR
in the absence of functional deterioration of kidney
function [30, 96–99]. Loupy et al. suggested that sub-
clinical TCMR was not associated with a significant
effect on allograft outcome but triggered the appear-
ance of de novo DSAs and progression to TG in a
subset of patients. They also showed that subclinical
ABMR detected at the 1-year screening biopsy carried
prognostic value independent of initial DSA status,
previous immunological events, current eGFR, and
proteinuria [100]. Further studies with longer follow-
up are required to determine whether surveillance bi-
opsies, combined with enhanced immunosuppression,
administered for the treatment of subclinical rejec-
tion, improve long-term outcomes.
Plasma cell-rich acute rejection (PCAR)
PCAR is a morphological type of acute rejection
with prominent plasma cells, which normally ac-
count for >10% of interstitial mononuclear cells
[101–104] (Fig. 3c). The histological diagnosis of
PCAR requires consideration of post-transplant lym-
phoproliferative disorder (PTLD), viral infection, and
drug toxicity. In previous studies, the response to an-
tirejection therapy in PCAR, such as steroids, was less
than satisfactory, with poor graft survival rates [105].
Some reports support the hypothesis that an
antibody-mediated component participates in the graft
injury of PCAR because it can be associated with
both C4d staining and DSAs [99, 103, 106]. If there
appears to be rapid progression of allograft dysfunc-
tion in the setting of significant plasma cell infiltra-
tion, then treatment modalities targeting both cellular
and antibody-mediated pathways can be considered,
although there are no data to support this line of
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infiltrate with slow progression of allograft dysfunc-
tion, it is unclear whether therapies used in the set-
ting of ABMR are of any benefit, and augmentation
of the maintenance immunosuppressive regimen may
be the best approach. Abbas et al. reported that
PCAR occurs late after transplantation and in many
cases associated with DSAs. Graft outcome was poor
when PCAR was associated with DSAs [107]. Due to
the rarity of PCAR, its incorporation into the Banff
classification is still awaited. Recognition of this en-
tity, description of more cases in the literature, and
further molecular approaches would help in determin-
ing its clinical features and appropriate therapeutic
approaches. The differential diagnosis of PCAR in-
cludes polyomavirus allograft nephropathy (PVN),
PTLD, and cytomegalovirus infection. Therefore,
SV40 staining, light chain (kappa and lambda) stain-
ing, and EBER (Epstein-Barr encoded early RNAs)
were useful to diagnose PCAR.CNI nephrotoxicity
CNIs are fundamental maintenance immunosuppres-
sants but, ironically, these drugs can cause renal toxicity
by several mechanisms. The histological features can be
divided into two types, acute and chronic nephrotoxicity,
and the target lesions involve the glomeruli, arterioles,
and tubulo-interstitium. Acute CNI nephrotoxicity in-
clude TMA, afferent arteriolar vasoconstriction, and iso-
metric vacuolization of tubules, whereas chronic CNI
nephrotoxicity includes glomerulosclerosis, arteriolar
hyaline thickening, and IF/TA [108]. CNI nephrotoxicity
also affects recipients with non-renal organ transplant-
ation. Indeed, the risk of chronic renal failure at 10 years
after transplantation of a non-renal organ was reported
to be ~20% [107]. However, end-stage renal failure
caused by CNIs is uncommon, at 3.2–4.8% [109, 110].
For kidney transplantation, the actual occurrence rates
at 5 and 10 years after kidney transplantation were 66
and 100%, respectively [111].Characteristic histological manifestations of acute CNI
nephrotoxicity
Early histopathological changes in glomerular capillaries
include fibrin thrombi and endothelial cell swelling.
These TMA-like changes range from mild to severe, and
mild changes occur sometimes with no clinical sign.
Afferent arterioles are likely to be affected by CNI
nephrotoxicity and the histopathology shows smooth
muscle cell swelling and ballooning in early changes. Re-
garding tubular injury, the straight portions of proximal
tubules are likely to be affected. An isometricvacuolization, characterized by small vacuoles filled to
normal-size tubular epithelial cells, is an early change in
CNI nephrotoxicity [112] (Fig. 3d).
Characteristic histological manifestations of chronic CNI
nephrotoxicity
Late histopathological changes in glomerular capillaries
include the thickening and duplication GBM. These
changes are believed to result from the remodeling
action induced by chronic CNI endothelial cell injury
[113]. The nodular hyaline deposits, which are replaced
by the necrotic smooth muscle cells of the media, are
distinct features of late changes in CNI nephrotoxicity
(Fig. 3e) [114]. In chronic tubular injury, IF/TA may
occur but such changes are non-specific.
Therapy for CNI nephrotoxicity
To reduce CNI nephrotoxicity, the clinician should try
to control serum CNI concentrations to lower levels,
but such methodologies may induce rejection epi-
sodes. Recent data from CTOT-9 (Clinical Trial of
Transplantation) investigated a CNI withdrawal regi-
men in cases with an immunologically low risk of
rejection. However, 6 of 14 cases of CNI withdrawal
experienced acute rejection [115]. Also, ZEUS study
reported by Budde et al. demonstrated the develop-
ment of de novo DSA production after conversion
from cyclosporine to everolimus [116]. Additionally,
Gallon et al. investigated the conversion from CNI to
sirolimus. It was concluded that renal function was
equal between the groups but the sirolimus group
showed activation of IL6 and IFN-γ, suggesting indirect
alloreactive T cell activation [117].
Polyomavirus infection
Polyomavirus allograft nephropathy (PVN), typically associ-
ated with BK virus, is caused by re-activation of latent intra-
graft polyomaviruses under immunosuppression. PVN was
first described by Mackenzie in 1978 [118], and subsequent
reports described the importance of PVN in patients with
kidney transplantation. Approximately 30–50% of recipi-
ents demonstrate viruria by cytology or polymerase chain
reaction within the first 3 months after kidney transplant-
ation and PVN can occur at the average time of 10–
14 months, but as early as 6 days and as late as 6 years,
after kidney transplantation [119]. The prevalence of PVN
was reportedly 1–10 and 20% of PVN cases showed graft
failure [120].
The key to diagnosing PVN is the histological fea-
tures of the epithelial cells: the so-called ground-glass
intranuclear inclusion body, cell lysis, necrosis, shed-
ding into the tubular lumen, denudation of tubular
basement membrane, interstitial inflammation, tubuli-
tis, IF/TA, and the positivity of these cells for SV40
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clude a high rate of false-negative biopsies, difficulties
in distinguishing TCMR, the presence of CMV infec-
tion, and persistence, for months to years [122–126].
Characteristic histological manifestations of polyomavirus
infection
The target lesions in PVN are epithelial cells of the
collecting duct, tubules, and Bowman’s capsule (parietal
epithelial cells). PVN may spread from the urothelium and
medulla to the ascending parts of the tubules and
Bowman’s capsule. Thus, if the foci of parenchymal involve-
ment are smaller, there may be a higher rate of false-
negative biopsies. To diagnose early PVN, it is important to
pay attention to the depth zones of the kidney samples
(medullary ray and medulla). The distinctive histological
findings of PVN consist of four types. The most common
type is (1) the ground-glass intranuclear inclusion body,
followed by (2) a central intranuclear inclusion body
surrounded by a halo, (3) nuclear enlargement and fine
granular and vesicular changes, and (4) clumped changes
[122] (Fig. 4a). The positivity of SV40 T antigen staining is
also helpful and indicates polyomavirus replication [124]
(Fig. 4b). Banff Polyomavirus Working Group has
performed multicenter retrospective study to develop the
histological staging system of this disease. AST (American
Society of Transplantation) staging system focuses on inter-
stitial inflammation and fibrosis [127], and Banff Working
Proposal 2009 focused on tubular cell shedding and fibrosisFig. 4 Pathological findings of BK virus nephropathy. a Tubular epithelial cells w
arrow) or intranuclear inclusion body surrounded by a halo (white arrow) in a pa
BK virus nephropathy. Distal tubular epithelial cells showed scattered nuclear SV[22]. Both systems did not show significant predictive value
in a single center study [121]. In 2013, Banff Working
Group proposed a new staging system consists of in situ
viral load (pvl score) and interstitial fibrosis and now under
consideration to incorporate official Banff criteria [128].
Treatment of polyomavirus infection
Specific antiviral drugs for polyomavirus infections are
not yet available; thus, patient screening and early diag-
nosis remain important. Therapeutic methods consist
primarily of reduced maintenance immunosuppression
proposed in AST guideline [127]. However, clinicians
should be aware that about one-quarter of patients
experience acute rejection during such a reduction in
immunosuppressive therapy [126]. Beyond serum CNI
concentrations, mycophenolic acid monitoring is also
useful in the clinical setting [129]. In terms of a preventive
protocol, low-dose maintenance tacrolimus showed de-
creased PVN [130]. Of note, Johnston et al. reported the
effect of cidofovir and leflunomide for PVN in meta-
analysis [131].
Recurrent disease
Graft loss due to recurrent native kidney disease had
been thought to be rare and the prevalence was esti-
mated at 1.8% in Japan (http://www.asas.or.jp/jst/pdf/
factbook/factbook2015.pdf ). However, several recent
reports suggest that recurrent kidney disease could con-
tribute more than had been estimated previously. Toere swelling and showed ground-glass intranuclear inclusion body (black
tient with BK virus nephropathy. b SV40 immunostaining in a patient with
40 positivity (arrow)
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nosis of the native kidney biopsy together with the
kidney allograft biopsy. Importantly, the timing or cri-
teria for episode or protocol biopsies differ by institu-
tion; these differences can affect the rate and period of
the recurrent disease. In most cases, estimations of the
recurrence rate for native kidney disease based on proto-
col biopsies showed higher recurrence rates (Table 3).
Immunoglobulin A neuropathy/immunoglobulin A (IgAN/
IgA) vasculitis
The reported recurrence rates of IgAN after transplantation
vary between 30 and 35%. The diagnosis of IgAN recur-
rence requires the presence of mesangial deposits and
hyperplasia in the graft, as well as known primary IgAN.
IgAN recurrence occurs typically more than 3 years after
transplantation. The risk of graft loss due to IgAN recur-
rence ranged from 3 to 5% [132]. Compared with IgAN,
relatively little is known about recurrent IgA vasculitis in
renal allografts. The recurrence rate ranges from 15 to 53%,
and graft loss due to recurrent IgA vasculitis was 7.5–28.6%
in different observation periods [133–135]. A large case-
controlled study of 318 patients from one center showed
no difference in 10-year graft survival between patients with
IgAN recurrence and non-IgAN matched controls: 75%
versus 82% [136]. However, it is possible that IgAN recur-
rence represents a risk factor for graft loss over the long
term.
Predictors of active IgAN recurrence include young age,
rapid progression of the original disease, and high serum
levels of galactose-deficient IgA1 and IgA-IgG complexes
[137–139]. Risk factors associated with recurrent IgA
vasculitis include shorter duration of the original disease,
a living related donor, and necrotizing/crescent glomer-
ulonephritis of the native kidneys [140]. No specific
therapy for IgAN and IgA vasculitis recurrence is avail-
able; guidelines recommend using angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers (ACEI/
ARBs) [141]. No immunosuppressive regimen has been
shown to be superior [142]. There are some reports that a
tonsillectomy followed by steroid pulse therapy resulted inTable 3 Recurrence rate and consequent graft loss risk of
glomerular disease
Recurrence rate Graft loss risk
IgAN 30–35% 3–5%
IgA vasculitis (HSPN) 15–53% 7.5–21%
FSGS 30–60% ~50%
MN 30–45% 10–50%
MPGN type I 30–50% ~15%
MPGN type II (DDD) 66–100% 34–66%
IgAN IgA nephroathy, HSPN Henoch Schonlein purpura nephritis, FSGS focal
segmental glomerulosclerosis, MN membranous nephropathy, MPGN
membranoproliferative glomerulonephritis, DDD dense deposit diseasedecreased proteinuria and improved renal function and
pathological findings of recurrent IgAN and IgA vasculitis
in a renal allograft [143–146].
FSGS
The reported risk of recurrence of focal segmental glo-
merulosclerosis (FSGS) in the first graft ranges from 30
to 60%, whereas the rate approaches 100% in subsequent
grafts [147]. Clinical features of FSGS recurrence include
the early and acute onset of massive proteinuria (hours
to days after transplantation). Risk factors for recurrence
include childhood onset, age <15 years, progression to
ESRD within 3 years of onset, diffuse increases in mesangial
cells in the native kidney, development of recurrent FSGS
in a previous allograft kidney, white race, and receiving a
kidney from an elderly donor [148, 149].
The existence of circulating permeability factors, pro-
posed by Savin’s group, may be a notable predictor of
FSGS recurrence [150]. Circulating urokinase receptor
(suPAR), which has been reported as a cause of FSGS,
may also be a predictor of FSGS recurrence [151]. How-
ever, the significance of suPAR is still controversial [152].
In addition, novel candidates such as CLC-1, anti-CD40
Ab, and vasodilator-stimulated phosphoprotein are pro-
posed [153]. The pathological significance of variant tran-
sition remains unknown. IJpelaar et al. [154] evaluated
variants of primary and recurrent FSGS for both native
and transplanted kidneys and found that 81% of patients
showed variant consistency between native and allograft
kidneys. They also found collapsing variant and cellular
variant (CELL) to be distinct disease entities that did not
change after transplantation [154]. In contrast, Canaud
et al. [155] reported several transitions between variants in
recurrent FSGS after transplantation. PE and immunoad-
sorption (IA) are effective treatments for recurrent FSGS
[148]. Ponticelli reported that partial or complete remis-
sion was achievable using PE or IA in 63% of adult
patients [148]. Rituximab is also known to be an ef-
fective treatment for FSGS and was more effective
with PE [156, 157]. However, other reports have
noted that rituximab showed an intermediate, or no,
response [158].
MN
Recurrence rates of membranous nephropathy (MN)
after kidney transplantation have been reported to be
30–45%. The disease usually occurs 2–3 years after
transplantation, negatively impacting graft survival with
a 10–50% rate of graft loss at 10 years [159]. Determin-
ation of the IgG subtypes within the immune deposits in
MN may be helpful in the differential diagnosis. IgG4 is
the predominant subtype in idiopathic MN and recur-
rent MN, which did not change over time in recurrent
MN [160]. Phospholipase A2 receptor (PLA2R) staining
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between recurrent and de novo MN. Larsen and Walker
reported that recurrent MN was correlated closely with
PLA2R positivity, with a sensitivity of 83% and a specifi-
city of 92% for recurrent MN [161]. Circulating anti-
PLA2R antibodies at the time of transplantation seems
to be a potential risk factor for MN recurrence [162].
Symptomatic treatment with diuretics, ACEI/ARBs, and
anticoagulants may be useful in recurrent MN with
nephritic syndrome. Some cases of complete responses
to therapy with steroids and cyclophosphamide have
been reported [163, 164]. Rituximab showed responses
more frequently in several, but not all, cases of MN
recurrence [165, 166].
MPGN
The traditional classification of membranoproliferative
glomerulonephritis (MPGN) was based on the location
and type of electron-dense deposits: type I was charac-
terized by subendothelial deposits, type II by intramem-
branous electron-dense deposits, and type III by
subendothelial and subepithelial deposits. The current
classification recognizes the importance of IF microscopy
in further dividing MPGN into immune complex-
mediated MPGN, with glomerular immunoglobulins and
complement deposition, and MPGN with abnormalities in
alternative complement pathway regulation, resulting in
isolated C3 deposits with little or no immunoglobulin by
IF(C3 glomerulopathy). MPGN type II is currently desig-
nated as dense deposit disease (DDD) and is recognized as
a variant of C3 glomerulopathy. C3 glomerulonephritis
(C3GN) refers to cases of C3 glomerulopathy in which the
electron-dense deposits do not have classic appearance
like DDD. The recurrence rate of DDD is 66–100% and
has the worst prognosis in MPGN. The rates of graft loss
due to recurrence ranges between 34 and 66% [167, 168].
A few patients may respond to plasma exchange [169].
Good results have been reported with eculizumab in DDD
patients [170, 171]. Fourteen of 21 (66.7%) patients with
C3GN developed recurrence at 28 months (median) after
transplantation. Graft failure occurred in 50% of patients
with recurrent C3GN after 77 months (median). The
remaining 50% of patients had functioning grafts, with a
median follow-up of 73.9 months [172]. MPGN type I
shows a high recurrence rate, of ~30–50% after trans-
plantation. Risk factors for recurrence include young
recipient age, aggressive disease in the native kidneys, and
persistently low complement levels. Recurrence occurs
early, usually in the first year post-transplantation. The
risk for graft loss is ~15% at 10 years [132].
Information on recurrence rates for MPGN type III is
limited. Little et al. [167] showed recurrence of MPGN
type III in 4 of 12 patients [33%]. Risk factors for recur-
rent MPGN type III were younger age at initial diagnosisand the presence of crescents on the original biopsy
[167].
Conclusions
The combination of molecular and conventional data will
provide new diagnostic criteria in the near future, but con-
ventional histopathology remains the gold standard for the
specific diagnosis of allograft dysfunction. Because kidney
allografts show considerable diversity, understanding the
basics of rejection, CNI nephrotoxicity, PVN, and native
kidney disease recurrence is essential for better kidney allo-
graft survival.
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